

ELFA MEDICAMENTOS S.A.

Corporate Taxpayer ID (CNPJ): 09.053.134/0001-45

Company's Registry (NIRE) 53.300.018.774

Publicly-Held Company with Authorized Share Capital

ELFA MEDICAMENTOS S.A. (the "Company"), informs that, as unanimously approved at the Company's Extraordinary General Meeting, held on July 7, 2023 and which was attended by 100% (one hundred percent) of the Company's shareholders, it was approved the repurchase of 4,745,079 (four million, seven hundred and forty-five thousand, seventy-nine) common, nominative, book-entry shares with no par value issued by the Company ("Shares"), held by the shareholders (i) Maria Helena Silveira; (ii) Renato Silveira Joiozo; and (iii) Simone Silveira Joiozo Lima ("Share Repurchase").

The annex contains information about the Repurchase of Shares pursuant to Annex G to CVM Resolution No. 80, of March 29, 2022. The minutes of the Company's Extraordinary General Meeting were made available on the Company's Investor Relations website and on CVM on July 10, 2023.

São Paulo, August 21, 2023.

ELFA MEDICAMENTOS S.A.

Clayton de Souza Malheiros

Chief Financial and Investor Relations Officer

Annex G to CVM Resolution No. 80, of March 29, 2022

1. Justify in detail the purpose and expected economic effects of the operation

The purpose of the Share Repurchase is to repurchase certain amount of shares issued by the Company held by the shareholders (i) Maria Helena Silveira; (ii) Renato Silveira Joiozo; (iii) and Simone Silveira Joiozo Lima ("Descarpack Shareholders"), upon payment of the amount of R\$ 50,000,000.00 (fifty million reais), adjusted pursuant to the Share Purchase and Sale Agreement and Other Covenants, entered into by the Company and the Descarpack Shareholders on October 18, 2021, as amended. Although the Share Repurchase has already been fully approved, the transfer of the Shares will occur until October 10, 2023, upon the respective payments.

2. Inform the number of shares (i) outstanding and (ii) already held in treasury

Before the Share Repurchase, the Company has a total of 211,303,212 (two hundred and eleven million, three hundred and three thousand, two hundred and twelve) common shares in circulation and 10,117,783 (ten million, one hundred and seventeen thousand, seven hundred and eighty and three) shares held in treasury.

3. Inform the number of shares that may be acquired or sold

The Share Repurchase comprises a total of 4,745,079 (four million, seven hundred and forty-five thousand, seventy-nine) registered, book-entry common shares of the Company with no par value.

4. Describe the main characteristics of the derivative instruments that the company may use, if any

Not applicable.

5. Describe, if any, any agreements or voting guidelines existing between the company and the counterparty of the operations

Company's Shareholders' Agreement, entered into on December 22, 2014, as amended from time to time and already made available by the Company to the market, to which both the Company and the shareholders involved in the Share Repurchase are parties.

6. In the event of transactions carried out outside organized securities markets, inform: a. the maximum (minimum) price at which the shares will be acquired (disposed of); and b. if applicable, the reasons that justify carrying out the operation at prices more than 10% (ten percent) higher, in the case of acquisition, or more than 10% (ten percent) lower, in the case of sale, to the average quotation, weighted by volume, in the 10 (ten) previous trading sessions

- a.) The 4,745,079 (four million, seven hundred and forty-five thousand, seventy-nine) common, registered, book-entry shares with no par value will be acquired for the amount of R\$ 50,000,000.00 (fifty million reais), adjusted pursuant to the Share Purchase and Sale Agreement and Other Covenants, entered into on October 18, 2021, and its amendments.
- b.) Not applicable, considering that the Company's shares are not traded in organized securities markets.

7. Inform, if any, the impacts that the negotiation will have on the composition of the shareholding control or the administrative structure of the company

The Share Repurchase will not impact the composition of the Company's shareholding control or administrative structure.

8. Identify the counterparties, if known, and, in the case of a party related to the company, as defined by the accounting rules that deal with this matter, also provide the information required by art. 9 of CVM Resolution No. 81, of March 29, 2022

The counterparties are: (i) Maria Helena Silveira; (ii) Renato Silveira Joiozo; and (iii) Simone Silveira Joiozo Lima, not being related parties of the Company.

9. Indicate the allocation of funds earned, if applicable

Not applicable.

10. Indicate the maximum period for the settlement of authorized operations

The liquidation of the Share Repurchased will be completed on October 10, 2023.

11. Identify institutions that will act as intermediaries, if any

Not applicable, considering that the operations will be carried out outside the exchange environment.

12. Specify the resources available to be used, pursuant to art. 8, paragraph 1, of CVM Resolution No. 77, of March 29, 2022

The resources that will be used in the Share Repurchase come from the Company's capital reserve.

13. Specify the reasons why the members of the board of directors feel comfortable that the repurchase of shares will not affect the fulfillment of obligations assumed with creditors or the payment of mandatory, fixed or minimum dividends.

The transaction was unanimously approved by the Company's shareholders, gathered at an Extraordinary General Meeting, in accordance with the terms of the Share Purchase and Sale Agreement and Other Covenants, entered into on October 18, 2021, as amended, not impacting compliance with the other obligations assumed by the Company.

* * * * *